BCRX
BioCryst Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 3
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
Bearish Abandoned Baby
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BCRX
Biocryst Pharmaceuticals, Inc.
A biotechn company that develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases
4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703
--
BioCryst Pharmaceuticals, Inc., a Delaware corporation, was originally established in 1986. The company is a global biotechnology company dedicated to improving the lives of patients with hereditary angioedema and rare diseases. Leveraging its expertise in structure-guided drug design, the company aims to develop first-in-class or first-in-class oral small molecule and injectable protein therapies for rare diseases that are difficult to treat.
Earnings Call
Q1/2025
Estimate EPS-0.05
Actual EPS0
Estimate Revenue127.79M
Actual Revenue134.20M
BioCryst Pharmaceuticals' Q1 2025: Unraveling Contradictions in ORLADEYO's Patient Rates and Market Potential
May 05,2025 10:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.03
Actual EPS0.15
Estimate Revenue149.82M
Actual Revenue163.35M
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics
Aug 04,2025 11:45
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.08
Actual EPS0.16
Estimate Revenue162.97M
Actual Revenue159.10M
BioCryst's Q3 2025: Contradictions Emerge on ORLADEYO Payer Position, Market Share, Paid Rates, and Pediatric Market Potential
Nov 03,2025 12:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BCRX has released its 2025 Q3 earnings. EPS was reported at 0.16, versus the expected 0.08, beating expectations. The chart below visualizes how BCRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BCRX has released its 2025 Q3 earnings report, with revenue of 159.40M, reflecting a YoY change of 36.14%, and net profit of 12.90M, showing a YoY change of 191.92%. The Sankey diagram below clearly presents BCRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
